We previously identified an intermediate β(2)-microglobulin (I-β(2) m), which is an amyloidogenic β(2) m variant, via capillary electrophoresis (CE) and reported hemodialysis (HD)-associated variations in the serum concentrations of each β(2) m component, including that found in the rebound phase. Recent research has indicated that I-β(2) m can bind, via the SO(3)(-) moiety, with glycosaminoglycan or proteoglycan, which are major components of interstitial tissue. Because alterations in I-β(2) m are likely to be important in view of the possible accumulation of amyloidogenic precursor proteins in the interstitial space, we studied the I-β(2) m profile as related to HD. We used CE to determine the I-β(2) m profile both at the start and at the end of HD and during the rebound phase in 12 HD patients. We found both an unfolded β(2) m and a destructured I-β(2) m. More important, two peaks appeared in the rebound phase, one suggesting a refolding and one suggesting an irreversible destruction. Given that the intercompartmental transfer coefficient for β(2) m is 1.0, our results indicated concomitant processes occurring after HD: refolding of the β(2) m conformation and trapping of destructured I-β(2) m in the extravascular space. Because the trapping of destructured I-β(2) m supposedly leads to accumulation of β(2) m in the interstitial space, we have proposed a new concept-a "shuttle" concept-for amyloid formation from β(2) m in the HD setting.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/j.1744-9987.2012.01069.x | DOI Listing |
Viruses
November 2024
Laboratório de Imunofarmacologia, Instituto Oswaldo Cruz (IOC), Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro 21040-361, RJ, Brazil.
Coronavirus disease 2019 (COVID-19) still causes death in elderly and immunocompromised individuals, for whom the sustainability of the vaccine response may be limited. Antiviral treatments, such as remdesivir or molnupiravir, have demonstrated limited clinical efficacy. Nirmatrelvir, an acute respiratory syndrome coronavirus 2 (SARS-CoV-2) major protease inhibitor, is clinically effective but has been associated with viral rebound and antiviral resistance.
View Article and Find Full Text PDFTransplant Proc
January 2025
Immunology Department, Immunopathology Group, Marqués de Valdecilla University Hospital-IDIVAL, Santander, Spain. Electronic address:
Background/aim: Despite the donor-exchange program implementation for highly sensitized (HS) patients, no improvement in waiting list in those HS patients with 100% calculated panel reactive of antibodies (cPRA) is observed. Recently, it has been published the treatment with imlifidase in desensitization algorithm. However, there are low-risk strategies to reduce cPRA.
View Article and Find Full Text PDFEnviron Sci Technol
January 2025
Water Research Centre, School of Civil and Environmental Engineering, The University of New South Wales, Sydney, New South Wales 2052, Australia.
The global atmospheric greenhouse gas (GHG) accumulation trajectory has been subjected to fluctuations in the context of the COVID-19 pandemic. Country-level virus prevalence and geography conditions added complexity to understanding atmospheric GHG accumulation sensitivities in terms of the growth rate. Here, extensive data sets were comprehensively analyzed to capture historical and projected fate of atmospheric GHG concentrations.
View Article and Find Full Text PDFTop Antivir Med
August 2024
New York Blood Center, New York, New York, USA.
Data on the HIV care cascade demonstrated challenges in achieving Ending the HIV Epidemic (EHE) targets across all 18 EHE focus metropolitan areas, but innovative adherence interventions using point-of-care tenofovir testing and motivational interviewing support care cascade outcomes in Namibia and South Africa, respectively. Data on treatment with long-acting injectable (LAI) antiretroviral therapy (ART) demonstrated high acceptability, retention, and virologic suppression including in groups that were not well represented in clinical trials including persons born female and persons with detectable viral loads. The adjuvanted hepatitis B vaccine appeared to be safe and appeared to be superior to conventional hepatitis B vaccines in persons with HIV (PWH) who were prior nonresponders to the hepatitis B vaccine.
View Article and Find Full Text PDFAntiviral Res
December 2024
Program for Experimental & Theoretical Modeling, Division of Hepatology, Department of Medicine, Stritch School of Medicine, Loyola University Chicago, Maywood, IL, USA. Electronic address:
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!